Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

The aims of the present study were to establish the maximally tolerated dose (MTD) of the histone deacetylase inhibitor valproate together with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with diffuse large B-cell lymphoma (DLBCL). A phase 1 dose escala...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Drott, Kristina, Hagberg, Hans, Papworth, Karin, Relander, Thomas, Jerkeman, Mats
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2018
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6020808/
https://ncbi.nlm.nih.gov/pubmed/29903707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019240
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak